# IMNM catalysts: Immunome Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/imnm/catalysts

> Immunome Inc. (IMNM) has 1 upcoming catalyst. The next is the varegacestat PDUFA date, April 28, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for IMNM?

Immunome Inc. (IMNM) has 1 upcoming catalyst. The next is the varegacestat PDUFA date, April 28, 2027. Press release filed with the SEC (EX-99): "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" [Calendar and source filings](https://sec-api.dev/companies/imnm/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-453556, https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/imnm/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Immunome Inc. |
| Ticker | IMNM (Nasdaq) |
| SEC CIK | 1472012 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/imnm |

## Cash runway

Cash $461.6M as of 2026-09-30; quarterly burn $60.8M; about 22.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-453597).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2023 | [OGSIVEO® (nirogacestat) FDA approval](https://sec-api.dev/pdufa/nirogacestat) | IMNM |  | completed, approved | "With respect to varegacestat, we expect to compete with companies advancing treatments for desmoid tumors, including SpringWorks Therapeutics, Inc. In November 2023, SpringWorks received FDA approval for its oral gamma secretase inhibitor, OGSIVEO® (nirogacestat), for the treatment of adult patients with progressing tumors who require systemic treatment." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312525269603/imnm-20250930.htm)) |
| November 13, 2024 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports Third Quarter 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465924117682/tm2428220d1_ex99-1.htm)) |
| Dec 2024 | [IM-1021 trial start](https://sec-api.dev/pdufa/im-1021) | IMNM |  | completed | "We received IND clearance for IM-1021 in December 2024 and began dosing participants in our Phase 1 clinical trial in February 2025 with a starting dose of 2 mg/kg of adjusted ideal body weight." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)) |
| Q1 2025 | [IM-1021 trial start](https://sec-api.dev/pdufa/im-1021) | IMNM |  | scheduled | "Our investigational new drug application (IND) for IM-1021, a receptor tyrosine kinase-like orphan receptor 1 (ROR1) antibody-drug conjugate (ADC) received clearance in December 2024, and we expect to initiate a phase 1 trial in the first quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/tm254675d1_8k.htm)) |
| Feb 2025 | [IM-1021 trial start](https://sec-api.dev/pdufa/im-1021) | IMNM |  | completed | "IM-1021: The Phase 1 clinical trial of IM-1021 is ongoing, with the first patient dosed in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_ex99-1.htm)) |
| March 19, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_ex99-1.htm)) |
| March 31, 2025 | [Varegacestat trial start](https://sec-api.dev/pdufa/varegacestat) | IMNM |  | completed | "(2) The increase for the three months ended March 31, 2025 compared to the three months ended March 31, 2024 was due primarily to increased clinical trial activities as we initiated our Phase 1 trial in February 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000155837025007382/tmb-20250331x10q.htm)) |
| May 8, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925047304/tm2514592d1_ex99-1.htm)) |
| 2H 2025 | [Immunome Inc. topline data readout](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | scheduled | "Enrollment in a Phase 3 registrational trial was completed in February 2024, and we expect to report topline data from this trial in the second half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000095017025104035/imnm-20250630.htm)) |
| August 6, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000095017025104015/imnm-ex99_1.htm)) |
| late 2025 | [Varegacestat topline data readout](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | scheduled | "We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_ex99-1.htm)) |
| November 6, 2025 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312525269538/imnm-ex99_1.htm)) |
| December 3, 2025 | [Varegacestat primary completion](https://sec-api.dev/pdufa/varegacestat) | IMNM | Desmoid; Desmoid Tumor | completed | "NCT04871282 (A Study of AL102 in Patients With Progressing Desmoid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2025-12-03 (ACTUAL); Lead Sponsor Immunome, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04871282)) |
| December 15, 2025 | [Varegacestat topline data readout](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | completed, positive | "On December 15, 2025, Immunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm)) |
| early 2026 | [IM-3050 trial start](https://sec-api.dev/pdufa/im-3050) | IMNM |  | scheduled | "IM-3050: Immunome previously received IND clearance for IM-3050 and plans to initiate a Phase 1 study in early 2026 after delivery of third-party diagnostic radiotracer supply." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm)) |
| Mar 2026 | [IM-3050 trial start](https://sec-api.dev/pdufa/im-3050) | IMNM | FAP-expressing solid tumors | completed | "IM-3050: In March 2026, Immunome initiated the first clinical trial site for a Phase 1 trial of IM-3050 in patients with FAP-expressing solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm)) |
| March 3, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm)) |
| Q2 2026 | [Varegacestat NDA/BLA submission](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors planned for 2Q 2026 | scheduled | "New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm)) |
| Q2 2026 | [IM-1617 trial start](https://sec-api.dev/pdufa/im-1617) | IMNM |  | scheduled | "IM-1617: In April 2026, Immunome received IND clearance for IM-1617 and plans to initiate a Phase 1 trial in the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm)) |
| Apr 2026 | [Varegacestat NDA/BLA acceptance](https://sec-api.dev/pdufa/varegacestat) | IMNM |  | completed | "We are monitoring these regulations as several of our programs move into later stages of development, including varegacestat for which we submitted an NDA in April 2026, which was accepted by the FDA and assigned a PDUFA date of April 28, 2027; however, a majority of our programs are currently in the earlier stages of development and we will not be able to assess the impact of price regulations for a number of years." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)) |
| Apr 2026 | [Varegacestat NDA/BLA submission](https://sec-api.dev/pdufa/varegacestat) | IMNM | with desmoid tumors | completed | "In April 2026, Immunome submitted an NDA to the U.S. FDA for varegacestat for the treatment of adults with desmoid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm)) |
| May 12, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-ex99_1.htm)) |
| Jun 2026 | [IM-1617 trial start](https://sec-api.dev/pdufa/im-1617) | IMNM | advanced solid tumors | completed | "IM-1617: In June 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-1617 in patients with advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| Jul 2026 | [Varegacestat NDA/BLA acceptance](https://sec-api.dev/pdufa/varegacestat) | IMNM |  | completed | "The U.S. FDA accepted the varegacestat NDA in July 2026 and assigned a PDUFA target action date of April 28, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| Jul 2026 | [IM-3050 trial start](https://sec-api.dev/pdufa/im-3050) | IMNM | FAP-expressing solid tumors | completed | "IM-3050: In July 2026, the first patient was dosed in the Phase 1, first-in-human trial evaluating IM-3050 in patients with FAP-expressing advanced solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| August 11, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526344577/imnm-ex99_1.htm)) |
| late 2026 | [IM-1340 trial start](https://sec-api.dev/pdufa/im-1340) | IMNM | advanced solid tumors | scheduled | "IM-1340, a potential first-in-class ADC, received investigational new drug, or IND, clearance in September 2026, and we plan to initiate a Phase 1 trial in patients with advanced solid tumors by the end of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)) |
| Nov 2026 | [IM-1021 interim data readout](https://sec-api.dev/pdufa/im-1021) | IMNM |  | scheduled | "In November 2026, we announced that initial clinical data from the ongoing Phase 1 trial of IM-1021 will be presented in a poster at the 68th American Society of Hematology, or ASH, Annual Meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453597/imnm-20260930.htm)) |
| November 9, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| April 28, 2027 | [Varegacestat PDUFA date](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | scheduled | "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |

## Drugs

- [IM-1021](https://sec-api.dev/pdufa/im-1021): 
- [IM-1340](https://sec-api.dev/pdufa/im-1340): advanced solid tumors
- [IM-1617](https://sec-api.dev/pdufa/im-1617): advanced solid tumors
- [IM-3050](https://sec-api.dev/pdufa/im-3050): fap-expressing solid tumors, fap-expressing advanced solid tumors
- [OGSIVEO® (nirogacestat)](https://sec-api.dev/pdufa/nirogacestat): 
- [Varegacestat](https://sec-api.dev/pdufa/varegacestat): progressing desmoid tumors, desmoid tumors, with desmoid tumors, desmoid tumors planned for 2q 2026, Desmoid

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/imnm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IMNM catalysts: Immunome Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/imnm/catalysts

```bibtex
@misc{secapidev_companies_imnm_catalysts_20261116,
  title        = {IMNM catalysts: Immunome Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/imnm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_imnm_catalysts_20261116","title":"IMNM catalysts: Immunome Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/imnm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
